Medicine and Dentistry
Patient
100%
Therapeutic Procedure
43%
Platinum
40%
Niraparib
39%
Bevacizumab
37%
Placebo
37%
Progression Free Survival
31%
Ovarian Cancer
30%
Doxorubicin
26%
Inpatient
25%
Overall Survival
22%
Neoplasm
21%
Surgery
20%
Recurrent Ovarian Cancer
18%
Diseases
16%
Carboplatin
16%
Woman
16%
Combination Therapy
15%
Krukenberg Tumor
15%
Tissues
14%
Panitumumab
14%
Hazard Ratio
14%
Primary Tumor
12%
Quality of Life
11%
Adverse Event
11%
Toxicity
10%
BRCA Mutation
9%
Paclitaxel
8%
Gemcitabine
8%
Intensity Modulated Radiation Therapy
7%
Follow up
7%
Maintenance Therapy
7%
Survival
6%
Arm
6%
Nodular Melanoma
6%
Vagina
6%
Case Report
6%
Disease Exacerbation
6%
Intention-to-Treat Analysis
5%
Homologous Recombination
5%
Systemic Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
43%
Platinum
40%
Bevacizumab
37%
Progression Free Survival
31%
Ovary Cancer
28%
Doxorubicin
26%
Overall Survival
22%
Neoplasm
21%
Diseases
16%
Carboplatin
16%
Ovary Carcinoma
15%
Panitumumab
14%
Complication
13%
Primary Tumor
12%
Symptom
12%
Adverse Event
11%
Toxicity
10%
Death
8%
Paclitaxel
8%
Gemcitabine
8%
Survival
6%
Melanoma
6%
Disease Exacerbation
6%
Nursing and Health Professions
Patient
39%
Bevacizumab
34%
Chemotherapy
19%
Niraparib
18%
Woman
15%
Carboplatin
14%
Progression Free Survival
13%
Ovary Cancer
12%
Complication
12%
Doxil
12%
Standard
11%
Quality of Life
11%
Diseases
10%
Overall Survival
8%
Platinum
8%
Intensity Modulated Radiation Therapy
7%
Paclitaxel
7%
Dose
7%
Patient-Reported Outcome
6%
Symptom
6%
Melanoma
6%
Follow up
5%
Inpatient
5%
Toxicity
5%